Search - tctmd.com

Displaying 221 - 240 of 412

Sort: Relevancy | Date

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

October 07, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

News Conference News HFSA 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

October 04, 2022

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

News Daily News

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

Michael O'Riordan

October 03, 2022

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

News Daily News

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

September 09, 2022

Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial

Presentation ESC 2022

Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial

Presenter: Otavio Berwanger

August 29, 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

August 27, 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

News Conference News ESC 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

August 27, 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

No Hints of Cognitive Defects With ARNIs in HFpEF

News Conference News ESC 2022

No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE

August 26, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

TCTMD’s Top 10 Most Popular Stories for July 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2022

August 01, 2022

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

July 25, 2022

TCTMD’s Top 10 Most Popular Stories for June 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2022

July 04, 2022

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

June 21, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Patch-Pump Delivery of Subcutaneous Furosemide Opens Options in HF

News Conference News ESC Heart Failure 2022

Patch-Pump Delivery of Subcutaneous Furosemide Opens Options in HF

May 26, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.